NHP Announces Dividends and Rebranding

By Bobby Samwell • Saturday, December 21 15:25 • Permanent Link

National Healthcare Properties, Inc. (NHP) has announced its intention to continue paying dividends on a quarterly basis on its 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock at an annualized rate of $1.84375 per share or $0.4609375 per share on a quarterly basis. The dividend of $0.4609375 per share is payable on January 15, 2025, to Series A preferred stock holders of record at the close of business on January 3, 2025.

Additionally, NHP intends to continue paying dividends on a quarterly basis on its 7.125% Series B Cumulative Redeemable Perpetual Preferred Stock at an annualized rate of $1.78125 per share or $0.4453125 per share on a quarterly basis. The dividend of $0.4453125 per share is also payable on January 15, 2025, to Series B preferred stock holders of record at the close of business on January 3, 2025.

Following its internalization and rebranding to National Healthcare Properties, effective as of market open on January 2, 2025, the NASDAQ ticker symbols for the Series A and Series B preferred stock will be changed from "HTIA" and "HTIBP" to "NHPAP" and "NHPBP," respectively. These changes require no action from stockholders.

As of now, the Series A and Series B preferred stock will continue to be listed on NASDAQ with no changes to their CUSIP numbers. Today the company's shares have moved 0.0% to a price of $14.2. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.